AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8391063 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 307
Study 8391063 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A
Number of subjects: 307
Study 8391063 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 307
Study 2881481 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (300 micrograms/kg/min)
Number of subjects: 20
Study 2881481 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside (10 micrograms/kg/min)
Number of subjects: 20
Study 31994479 — intervention group
Group type: EXPERIMENTAL
Intervention: 2016 ACR-EULAR criteria
Number of subjects: 350
Study 31994479 — intervention group
Group type: EXPERIMENTAL
Intervention: AECG criteria
Number of subjects: 350
Study 31994479 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR criteria
Number of subjects: 350
Study 28862483 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer change agent intervention (PrEP/peer change agent training workshop followed by booster calls for 12 months)
Number of subjects: 423
Study 28862483 — intervention group
Group type: COMPARATOR
Intervention: Minimal contact attention control (sex diary activity)
Number of subjects: 423
Study 27511742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum (3 g/day for 16 weeks)
Number of subjects: 84
Study 27511742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum with Cordyceps sinensis (3 g/day for 16 weeks)
Number of subjects: 84
Study 27511742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 23629946 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise pause
Number of subjects: 12
Study 23629946 — intervention group
Group type: COMPARATOR
Intervention: relaxation pause
Number of subjects: 12
Study 23629946 — intervention group
Group type: COMPARATOR
Intervention: without pause
Number of subjects: 12
Study 23636087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided caudal epidural steroid injection
Number of subjects: 120
Study 23636087 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided caudal epidural steroid injection
Number of subjects: 120
Study 19924670 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg oral prednisolone for 10 days
Number of subjects: 52
Study 19924670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 19138994 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Number of subjects: 54
Study 19138994 — intervention group
Group type: COMPARATOR
Intervention: Intensive inspection
Number of subjects: 54
Study 19138994 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 54
Study 16380544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg/d riboflavin for 12 weeks
Number of subjects: 35
Study 16380544 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 35
Study 14964680 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine applied before or after acid etching
Number of subjects: 24
Study 14964680 — intervention group
Group type: COMPARATOR
Intervention: Control groups with no chlorhexidine application
Number of subjects: 24
Study 10379275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser (1 W, 15 pps, 1 s)
Number of subjects: 38
Study 10379275 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 38
Study 8882239 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope (size 3) in standard Macintosh configuration followed by activation of the distal hinged tip
Number of subjects: 102
Study 1354225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine, 15 mg twice a day (6 patients)
Number of subjects: 12
Study 1354225 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 patients)
Number of subjects: 12
Study 6238133 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (vasopressin derivative) administered for 10 days, 40 micrograms per day
Number of subjects: 9
Study 31046500 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing every 2 months until 12 months (Groups 2, 3, and 4)
Number of subjects: 106
Study 31046500 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback-enhanced testing at 6 months (Group 3)
Number of subjects: 106
Study 31046500 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback-enhanced testing at 2, 6, and 10 months (Group 4)
Number of subjects: 106
Study 31046500 — intervention group
Group type: COMPARATOR
Intervention: No testing until 12 months (Group 1)
Number of subjects: 106
Study 27864620 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside-out or Outside-in TO-TVT
Number of subjects: 46
Study 26453645 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV IgG antibody levels
Number of subjects: 468
Study 26453645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine levels
Number of subjects: 468
Study 26453645 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of EBNA-1 IgG levels
Number of subjects: 468
Study 26453645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine levels >25 ng/mL
Number of subjects: 468
Study 23350967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia (VT) ablation
Number of subjects: 95
Study 23350967 — intervention group
Group type: COMPARATOR
Intervention: ICD only treatment
Number of subjects: 95
Study 21263058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (1 mg/kg)
Number of subjects: 80
Study 21263058 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Fentanyl (1 μg/kg)
Number of subjects: 80
Study 21263058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (1 mg/kg) and IV Fentanyl (1 μg/kg)
Number of subjects: 80
Study 21263058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19136368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care (model A) using home autoadjusting positive airway pressure to set therapeutic CPAP, supervised by an experienced nurse.
Number of subjects: 619
Study 19136368 — intervention group
Group type: COMPARATOR
Intervention: Physician-led care (model B) involving two laboratory polysomnograms to diagnose and treat OSA, supervised by a sleep physician.
Number of subjects: 619
Study 19136368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care (model A)
Number of subjects: 619
Study 19136368 — intervention group
Group type: COMPARATOR
Intervention: Physician-led care (model B)
Number of subjects: 619
Study 17211873 — intervention group
Group type: COMPARATOR
Intervention: Psychological Screening Inventory (PSI)
Number of subjects: 0
Study 15115576 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-group (high climate temperature, n=6)
Number of subjects: 6
Study 15115576 — intervention group
Group type: COMPARATOR
Intervention: I Control-group (n=10)
Number of subjects: 6
Study 15115576 — intervention group
Group type: COMPARATOR
Intervention: II Control-group (n=9)
Number of subjects: 6
Study 11895966 — intervention group
Group type: EXPERIMENTAL
Intervention: WRSS1 vaccine (3 x 10(3) CFU)
Number of subjects: 34
Study 11895966 — intervention group
Group type: EXPERIMENTAL
Intervention: WRSS1 vaccine (3 x 10(4) CFU)
Number of subjects: 34
Study 11895966 — intervention group
Group type: EXPERIMENTAL
Intervention: WRSS1 vaccine (3 x 10(5) CFU)
Number of subjects: 34
Study 11895966 — intervention group
Group type: EXPERIMENTAL
Intervention: WRSS1 vaccine (3 x 10(6) CFU)
Number of subjects: 34
Study 11895966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11895966 — intervention group
Group type: EXPERIMENTAL
Intervention: WRSS1 vaccine (all groups)
Number of subjects: 34
Study 9455517 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin prophylaxis (500 mg/week)
Number of subjects: 1016
Study 9455517 — intervention group
Group type: COMPARATOR
Intervention: Benzathine penicillin G (BPG)
Number of subjects: 1016
Study 9455517 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 1016
Study 7872318 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dialysis prescriptions
Number of subjects: 59
Study 7872318 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysis prescriptions (no change)
Number of subjects: 59
Study 7872318 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dialysis efficacy (Kt/V urea and nPCR of 1.28 and 1.22 g/kg/d)
Number of subjects: 59
Study 7872318 — intervention group
Group type: COMPARATOR
Intervention: Lower dialysis efficacy (Kt/V urea and nPCR of 1.09 and 1.01)
Number of subjects: 59
Study 2205161 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator (Cobe)
Number of subjects: 33
Study 2205161 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator (Polystan)
Number of subjects: 33
Study 2205161 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane oxygenator (SciMed)
Number of subjects: 33
Study 645142 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg glibenclamide daily
Number of subjects: 0
Study 645142 — intervention group
Group type: COMPARATOR
Intervention: Usual diet therapy
Number of subjects: 0
Study 7170283 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuckled breasts (intervention)
Number of subjects: 10
Study 7170283 — intervention group
Group type: COMPARATOR
Intervention: Suckled breasts (control)
Number of subjects: 10
Study 7170283 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurnal feeds (unsuckled)
Number of subjects: 10
Study 31179531 — intervention group
Group type: EXPERIMENTAL
Intervention: Artisanal medical CBD oil (2-5 mg/kg/day, up-titrated to a maximum of 25 mg/kg/day) added to baseline AED regimen for at least 6 months.
Number of subjects: 29
Study 29578103 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator (BD; ipratropium 0.5mg + salbutamol 2.5 mg)
Number of subjects: 20
Study 29578103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL; normal saline)
Number of subjects: 20
Study 26514352 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation
Number of subjects: 0
Study 26514352 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25068546 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (TCA) peeling 25%
Number of subjects: 65
Study 25068546 — intervention group
Group type: COMPARATOR
Intervention: Q-switched Nd:YAG laser
Number of subjects: 65
Study 25068546 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal type of melasma
Number of subjects: 65
Study 22799893 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0
Study 22799893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22799893 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cessation intervention
Number of subjects: 0
Study 22799893 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervention plus components to address weight concerns
Number of subjects: 0
Study 20601671 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 50 IU/kg/week
Number of subjects: 33
Study 20601671 — intervention group
Group type: COMPARATOR
Intervention: Control (no EPO treatment)
Number of subjects: 33
Study 17599427 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies used in the vanguard phase (chart and database review)
Number of subjects: 10251
Study 17599427 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies used in the main trial
Number of subjects: 10251
Study 17599427 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate start of enrollment by clinics at the beginning of the main trial
Number of subjects: 10251
Study 15109699 — intervention group
Group type: EXPERIMENTAL
Intervention: Lag-click condition
Number of subjects: 91
Study 15109699 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-click condition
Number of subjects: 91
Study 15109699 — intervention group
Group type: COMPARATOR
Intervention: Intensity levels (43, 58, or 73 dB)
Number of subjects: 91
Study 15109699 — intervention group
Group type: COMPARATOR
Intervention: Gender
Number of subjects: 91
Study 11401877 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycophosphopeptical (Inmunoferón) at oral doses of 3 g/d for 90 days
Number of subjects: 60
Study 11401877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9184521 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection drug use history among homeless men in Baltimore
Number of subjects: 368
Study 9184521 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection drug use history among homeless men in Boston
Number of subjects: 368
Study 9184521 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection drug use history among homeless women in Baltimore
Number of subjects: 368
Study 9184521 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection drug use history among homeless women in Boston
Number of subjects: 368
Study 8278664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideokinetic imagery
Number of subjects: 0
Study 8278664 — intervention group
Group type: COMPARATOR
Intervention: Flexibility combined with abdominal strength training
Number of subjects: 0
Study 3448513 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DTPA (intravenous contrast medium for MRI)
Number of subjects: 50
Study 3448513 — intervention group
Group type: COMPARATOR
Intervention: CT scanning without Gd-DTPA
Number of subjects: 50
Study 3448513 — intervention group
Group type: COMPARATOR
Intervention: MR scanning without Gd-DTPA
Number of subjects: 50
Study 3448513 — intervention group
Group type: EXPERIMENTAL
Intervention: MR scanning with Gd-DTPA
Number of subjects: 50
Study 29092879 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 egg/day for 6 months (n = 80)
Number of subjects: 163
Study 29092879 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group; n = 83)
Number of subjects: 163
Study 27775416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral/mindfulness-based group sleep intervention
Number of subjects: 144
Study 27775416 — intervention group
Group type: COMPARATOR
Intervention: Active control 'study skills' intervention
Number of subjects: 144
Study 24128286 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) training using a handheld computer for 4 months
Number of subjects: 100
Study 24128286 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in cravings reported on EMA prompts
Number of subjects: 100
Study 24128286 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping styles (distraction and disengagement)
Number of subjects: 100
Study 24128286 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping style (acceptance)
Number of subjects: 100
Study 22491480 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential therapy (IFT) delivered at high, to‐tolerance intensity and high AMF for 30 minutes
Number of subjects: 180
Study 22491480 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 180
Study 22491480 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 19852789 — intervention group
Group type: COMPARATOR
Intervention: DMSA (dimercapto succinic acid), 3 days for Phase 1, followed by 6 additional rounds in Phase 2
Number of subjects: 49
Study 19852789 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA (dimercapto succinic acid), 3 days for Phase 1
Number of subjects: 49
Study 19852789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 17237324 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral change communication intervention
Number of subjects: 198
Study 17237324 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 198
Study 15728754 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 90
Study 15728754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 15728754 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (40 mg/day - 120 mg/day)
Number of subjects: 90
Study 15728754 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 90
Study 11685055 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical autologous serum as a tear substitute
Number of subjects: 12
Study 11685055 — intervention group
Group type: COMPARATOR
Intervention: Unpreserved normal saline solution as a placebo
Number of subjects: 12
Study 9742917 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus early postoperative intraperitoneal chemotherapy (mitomycin C on day 1 and 5-fluorouracil on days 2-5)
Number of subjects: 248
Study 9742917 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus early postoperative intraperitoneal chemotherapy
Number of subjects: 248
Study 9742917 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 248
Study 7799589 — intervention group
Group type: EXPERIMENTAL
Intervention: Endolymphatic injection of gentamycin and myelopid
Number of subjects: 0
Study 3167272 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcomputer-based cognitive rehabilitation
Number of subjects: 3
Study 31727030 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed leaflet
Number of subjects: 11038
Study 31727030 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed leaflet
Number of subjects: 11038
Study 31727030 — intervention group
Group type: COMPARATOR
Intervention: Control condition (current national leaflet)
Number of subjects: 11038
Study 28621489 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil (5-FU)
Number of subjects: 932
Study 28621489 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control cream
Number of subjects: 932
Study 25164513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Number of subjects: 63
Study 25164513 — intervention group
Group type: COMPARATOR
Intervention: Health Education Control (HEC)
Number of subjects: 63
Study 23325582 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab treatment
Number of subjects: 241
Study 23325582 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 241
Study 21508863 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dose of hydroxyzine 50 mg
Number of subjects: 18
Study 21508863 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dose of hydroxyzine 50 mg
Number of subjects: 18
Study 21508863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19385022 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (10En%)
Number of subjects: 25
Study 19385022 — intervention group
Group type: COMPARATOR
Intervention: Casein protein (10En%)
Number of subjects: 25
Study 19385022 — intervention group
Group type: COMPARATOR
Intervention: Soy protein (10En%)
Number of subjects: 25
Study 19385022 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (25En%)
Number of subjects: 25
Study 19385022 — intervention group
Group type: COMPARATOR
Intervention: Casein protein (25En%)
Number of subjects: 25
Study 19385022 — intervention group
Group type: COMPARATOR
Intervention: Soy protein (25En%)
Number of subjects: 25
Study 18225471 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological home-based intervention involving up to 13 visits from an occupational therapist
Number of subjects: 272
Study 18225471 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group with nurse arm and one in-home session following trial completion at 6-months
Number of subjects: 272
Study 14985185 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) supplementation (0.8 or 1.6 g/kg body mass)
Number of subjects: 27
Study 14985185 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) supplementation during a 6-week period
Number of subjects: 27
Study 14985185 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) supplementation following a 40 km simulated cycling trial
Number of subjects: 27
Study 14985185 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 27
Study 11238499 — intervention group
Group type: EXPERIMENTAL
Intervention: MSH/ACTH(4-10)
Number of subjects: 36
Study 11238499 — intervention group
Group type: COMPARATOR
Intervention: desacetyl-alphaMSH
Number of subjects: 36
Study 11238499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9583444 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (2 mg bolus iv injection followed by continuous infusion of 2-6 mg/h for 3 hours)
Number of subjects: 70
Study 9583444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 7666817 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combination of estradiol valerate and cyproterone acetate (Climen)
Number of subjects: 402
Study 7666817 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3, 300 IU/day
Number of subjects: 402
Study 7666817 — intervention group
Group type: EXPERIMENTAL
Intervention: Climen + Vitamin D3
Number of subjects: 402
Study 7666817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 2669435 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser trabeculoplasty
Number of subjects: 39
Study 2669435 — intervention group
Group type: COMPARATOR
Intervention: Medication therapy
Number of subjects: 39
Study 1234508 — intervention group
Group type: EXPERIMENTAL
Intervention: SC‐23992 (50 mg)
Number of subjects: 0
Study 1234508 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (125 mg)
Number of subjects: 0
Study 1234508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31008717 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed microvascular tissue (PMVT)
Number of subjects: 3
Study 31008717 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 3
Study 29114095 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mechanical thrombectomy (MT)
Number of subjects: 360
Study 29114095 — intervention group
Group type: COMPARATOR
Intervention: Bridging therapy (intravenous thrombolysis plus MT)
Number of subjects: 360
Study 25975338 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal training (pig model)
Number of subjects: 0
Study 25975338 — intervention group
Group type: COMPARATOR
Intervention: Artificial simulator training
Number of subjects: 0